Cubist Systematic Strategies LLC bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 128,248 shares of the company's stock, valued at approximately $1,786,000. Cubist Systematic Strategies LLC owned 0.11% of Arcutis Biotherapeutics at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of ARQT. Venturi Wealth Management LLC purchased a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $46,000. Cibc World Markets Corp purchased a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $140,000. Summit Investment Advisors Inc. boosted its stake in shares of Arcutis Biotherapeutics by 8.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,245 shares of the company's stock valued at $157,000 after purchasing an additional 837 shares in the last quarter. LVW Advisors LLC purchased a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $166,000. Finally, Syon Capital LLC purchased a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $189,000.
Arcutis Biotherapeutics Trading Up 3.5%
Shares of Arcutis Biotherapeutics stock traded up $0.48 during trading hours on Friday, hitting $14.11. The company's stock had a trading volume of 1,817,496 shares, compared to its average volume of 2,306,789. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. Arcutis Biotherapeutics, Inc. has a twelve month low of $6.99 and a twelve month high of $17.75. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -7.88 and a beta of 1.87. The firm has a fifty day moving average of $14.69 and a 200-day moving average of $13.46.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. The company had revenue of $65.85 million during the quarter, compared to the consensus estimate of $64.80 million. Research analysts forecast that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have recently commented on ARQT shares. The Goldman Sachs Group raised their target price on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Thursday, February 27th. Guggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a research note on Thursday, April 3rd. HC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, April 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $20.00 price target on shares of Arcutis Biotherapeutics in a report on Wednesday, April 9th. Finally, Jefferies Financial Group boosted their target price on shares of Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $18.80.
Check Out Our Latest Analysis on ARQT
Insider Buying and Selling
In related news, insider Patrick Burnett sold 12,242 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $15.04, for a total value of $184,119.68. Following the transaction, the insider now directly owns 121,936 shares in the company, valued at approximately $1,833,917.44. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $13.00, for a total transaction of $130,000.00. Following the sale, the director now owns 131,944 shares in the company, valued at approximately $1,715,272. This trade represents a 7.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 36,662 shares of company stock valued at $527,326. Company insiders own 9.40% of the company's stock.
Arcutis Biotherapeutics Profile
(
Free Report)
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Further Reading
Before you consider Arcutis Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.
While Arcutis Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
